2407 — Gaush Meditech Income Statement
0.000.00%
- HK$797.12m
- HK$846.27m
- CNY1.43bn
- 67
- 96
- 14
- 66
Annual income statement for Gaush Meditech, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | PRESS |
Standards: | IFRS | IFRS | IFRS | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 962 | 1,298 | 1,254 | 1,406 | 1,428 |
Cost of Revenue | |||||
Gross Profit | 436 | 609 | 625 | 692 | 663 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 810 | 1,353 | 1,486 | 1,108 | 1,236 |
Operating Profit | 152 | -54.4 | -232 | 298 | 192 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 149 | -138 | -275 | 248 | 155 |
Provision for Income Taxes | |||||
Net Income After Taxes | 98.5 | -192 | -353 | 173 | 88.5 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 99.4 | -190 | -350 | 174 | 92.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 99.4 | -190 | -350 | 174 | 92.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.672 | -1.18 | -3.34 | 1.17 | 0.715 |
Dividends per Share |